News
BLRX
--
0.00%
--
Thinking about buying stock in Super League Gaming, Soligenix, Vascular Biogenics, BioLineRx, or electroCore?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SLGG, SNGX, VBLT, BLRX, and ECOR.
PR Newswire - PRF · 03/04 13:31
SKT, BLRX, LPCN and ECOR among premarket gainers
Severn Bancorp (SVBI) +82% on merger agreement with Shore Bancshares.Tanger Factory Outlet Centers (SKT) +21%.Allied Esports Entertainment Inc. (AESE) +19%.Bellicum Pharmaceuticals (BLCM) +14%. on first reported use of CaspaCIDe® Safety Switch.Soligenix
Seekingalpha · 03/04 13:24
Biolinerx (BLRX) Gets a Buy Rating from Maxim Group
In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Biolinerx (BLRX), with a price target of $5.00. The company's
SmarterAnalyst · 02/26 13:28
Penny Stocks Surge In February, 3 Cheap Stocks To Watch Now
Penny Stocks · 02/24 21:10
Biolinerx (BLRX) Gets a Buy Rating from Oppenheimer
In a report released yesterday, Mark Breidenbach from Oppenheimer maintained a Buy rating on Biolinerx (BLRX), with a price target of $10.00. The
SmarterAnalyst · 02/24 10:02
H.C. Wainwright Remains a Buy on Biolinerx (BLRX)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biolinerx (BLRX) yesterday and set a price target of $19.00. The company's shares
SmarterAnalyst · 02/24 07:15
DJ BioLine RX Price Target Cut to $19.00/Share From $22.00 by HC Wainwright & Co.
Dow Jones · 02/23 16:34
DJ BioLine RX Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 02/23 16:34
--Analyst Actions: HC Wainwright Adjusts BioLineRx' Price Target to $19 from $22, Keeps Buy Rating
MT Newswires · 02/23 12:47
BioLineRx Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 23, 2021 / BioLineRx Ltd. (NASDAQ:BLRX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 23, 2021 at 10:00 AM Eastern Time.
ACCESSWIRE · 02/23 12:45
biolinerx EPS beats by $1.06
biolinerx (BLRX): FY GAAP EPS of -$0.12 beats by $1.06.Cash, cash equivalents and short-term bank deposits of $22.6M.Press Release
Seekingalpha · 02/23 12:04
BioLineRx Reports Year-End 2020 Financial Results and Provides Corporate Update
, /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the year ended and provides a corporate update.
PR Newswire - PRF · 02/23 12:00
BioLineRx to Report Annual 2020 Results on February 23, 2021
, /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its audited financial results for the year ended on , before the US markets open.
PR Newswire - PRF · 02/17 12:00
The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 9)
Benzinga · 02/09 13:10
These 2 Penny Stocks Could Rally All the Way to $11, Say Analysts
TipRanks · 01/28 16:31
These 2 Penny Stocks Could Rally All the Way to $11, Say Analysts
At its January FOMC meeting, the Federal Reserve held interest rates steady – they are near rock-bottom now, and to no one’s surprise, the Fed is keeping them there. Fed Chairman Jerome Powell may have fed some market pessimism when he spoke after the meet...
TipRanks · 01/28 16:31
BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of the Option of the Underwriter
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced the closing of its previously announced underwritten offering of 14,375,000 American Depositary Shares (ADSs) of the Company, i...
PR Newswire · 01/22 21:15
BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of the Option of the Underwriter
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced the closing of its previously announced underwritten offering of 14,375,000 American Depositary Shares (ADSs) of the Company, i...
PR Newswire · 01/22 21:15
BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of the Option of the Underwriter
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced the closing of its previously announced underwritten offering of 14,375,000 American Depositary Shares (ADSs) of the Company, i...
PR Newswire · 01/22 21:15
BioLineRx Raises Gross Proceeds of $34.5 Million From ADS Offering
MT Newswires · 01/22 16:44
Webull provides a variety of real-time BLRX stock news. You can receive the latest news about BioLine RX through multiple platforms. This information may help you make smarter investment decisions.
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.